% Encoding: UTF-8

@Article{Longley2005,
  author    = {Longley, DB and Johnston, PG},
  title     = {Molecular mechanisms of drug resistance},
  journal   = {The Journal of pathology},
  year      = {2005},
  volume    = {205},
  number    = {2},
  pages     = {275--292},
  publisher = {Wiley Online Library},
}

@Article{Shah2002,
  author    = {Shah, Neil P and Nicoll, John M and Nagar, Bhushan and Gorre, Mercedes E and Paquette, Ronald L and Kuriyan, John and Sawyers, Charles L},
  title     = {Multiple {BCR-ABL} kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib ({STI571}) in chronic phase and blast crisis chronic myeloid leukemia},
  journal   = {Cancer Cell},
  year      = {2002},
  volume    = {2},
  number    = {2},
  pages     = {117--125},
  publisher = {Elsevier},
}

@Misc{FDA,
  author = {{U. S. Food and Drug Administration}},
  title  = {Hematology/Oncology (Cancer) Approvals \& Safety Notifications},
  year   = {2015},
  note   = {[Online; accessed 9-May-2015]},
  url    = {http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm},
}

@Article{Zhao2014,
  author    = {Zhao, Zheng and Wu, Hong and Wang, Li and Liu, Yi and Knapp, Stefan and Liu, Qingsong and Gray, Nathanael S},
  title     = {Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?},
  journal   = {ACS Chem. Biol.},
  year      = {2014},
  volume    = {9},
  number    = {6},
  pages     = {1230--1241},
  publisher = {ACS Publications},
}

@Misc{ACSreport,
  author    = {{American Cancer Society}},
  title     = {Cancer Facts \& Figures 2015},
  year      = {2015},
  note      = {[Online; accessed 7-May-2015]},
  publisher = {American Cancer Society},
  url       = {http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf},
}

@Article{Marias2011,
  author    = {Marias, K. and Dionysiou, D. and Sakkalis, V. and Graf, N. and Bohle, R. M. and Coveney, P. V. and Wan, S. and Folarin, A. and B{\"u}chler, P. and Reyes, M. and Clapworthy, G. and Liu, E. and Sabczynski, J. and Bily, T. and Roniotis, A. and Tsiknakis, M. and Kolokotroni, E. and Giatili, S. and Veith, C. and Messe, E. and Stenzhorn, H. and Kim, Yoo-Jin and Zasada, S. and Haidar, A. N. and May, C. and Bauer, S. and Wang, T. and Zhao, Y. and Karasek, M. and Grewer, R. and Franz, A. and Stamatakos, G.},
  title     = {Clinically driven design of multi-scale cancer models: the ContraCancrum project paradigm},
  journal   = {Interface Focus},
  year      = {2011},
  volume    = {1},
  number    = {3},
  pages     = {450--461},
  issn      = {2042-8898},
  abstract  = {The challenge of modelling cancer presents a major opportunity to improve our ability to reduce mortality from malignant neoplasms, improve treatments and meet the demands associated with the individualization of care needs. This is the central motivation behind the ContraCancrum project. By developing integrated multi-scale cancer models, ContraCancrum is expected to contribute to the advancement of in silico oncology through the optimization of cancer treatment in the patient-individualized context by simulating the response to various therapeutic regimens. The aim of the present paper is to describe a novel paradigm for designing clinically driven multi-scale cancer modelling by bringing together basic science and information technology modules. In addition, the integration of the multi-scale tumour modelling components has led to novel concepts of personalized clinical decision support in the context of predictive oncology, as is also discussed in the paper. Since clinical adaptation is an inelastic prerequisite, a long-term clinical adaptation procedure of the models has been initiated for two tumour types, namely non-small cell lung cancer and glioblastoma multiforme; its current status is briefly summarized.},
  doi       = {10.1098/rsfs.2010.0037},
  eprint    = {http://rsfs.royalsocietypublishing.org/content/1/3/450.full.pdf},
  publisher = {Royal Society},
  url       = {http://rsfs.royalsocietypublishing.org/content/1/3/450},
}

@Article{Sloot2009,
  author    = {Sloot, P.M.A. and Coveney, Peter V. and Ertaylan, G. and M{\"u}ller, V. and Boucher, C.A. and Bubak, M.},
  title     = {{HIV} decision support: from molecule to man},
  journal   = {Philosophical Transactions of the Royal Society of London A: Mathematical, Physical and Engineering Sciences},
  year      = {2009},
  volume    = {367},
  number    = {1898},
  pages     = {2691--2703},
  issn      = {1364-503X},
  abstract  = {Human immunodeficiency virus (HIV) is recognized to be one of the most destructive pandemics in recorded history. Effective highly active antiretroviral therapy and the availability of genetic screening of patient virus data have led to sustained viral suppression and higher life expectancy in patients who have been infected with HIV. The sheer complexity of the disease stems from the multiscale and highly dynamic nature of the system under study. The complete cascade from genome, proteome, metabolome and physiome to health forms a multidimensional system that crosses many orders of magnitude in temporal and spatial scales. Understanding, quantifying and handling this complexity is one of the biggest challenges of our time, which requires a highly multidisciplinary approach. In order to supply researchers with an interactive framework and to provide the medical professional with appropriate tools and information for making a balanced and reliable clinical decision, we have developed {\textquoteleft}ViroLab{\textquoteright}, a collaborative decision-support system (http://www.virolab.org/). ViroLab contains computational models that cover various spatial and temporal scales from atomic-level interactions in nanoseconds up to sociological interactions on the epidemiological level, spanning years of disease progression. ViroLab allows for personalized drug ranking. It is on trial in six hospitals and various virology and epidemiology laboratories across Europe.},
  doi       = {10.1098/rsta.2009.0043},
  eprint    = {http://rsta.royalsocietypublishing.org/content/367/1898/2691.full.pdf},
  publisher = {The Royal Society},
  url       = {http://rsta.royalsocietypublishing.org/content/367/1898/2691},
}

@Article{Sadiq2008,
  author      = {S. K. Sadiq and D. W. Wright and S. J. Watson and S. J. Zasada and I. Stoica and P.V. Coveney},
  title       = {{Automated Molecular Simulation Based Binding Affinity Calculator for Ligand-Bound HIV-1 Proteases}},
  journal     = {J. Chem. Inf. Model.},
  year        = {2008},
  volume      = {48},
  number      = {9},
  pages       = {1909--1919},
  issn        = {1549-9596},
  affiliation = {Centre for Computational Science, Department of Chemistry, University College London, London, WC1H 0AJ, U.K.},
  doi         = {10.1021/ci8000937},
  owner       = {dave},
  timestamp   = {2011.04.18},
}

@Article{Sadiq2010,
  author      = {S. K. Sadiq and D. W. Wright and O. A. Kenway and P. V. Coveney},
  title       = {{Accurate ensemble molecular dynamics binding free energy ranking of multidrug-resistant HIV-1 proteases}},
  journal     = {J. Chem. Inf. Model.},
  year        = {2010},
  volume      = {50},
  number      = {5},
  pages       = {890--905},
  abstract    = {Accurate calculation of important thermodynamic properties, such as macromolecular binding free energies, is one of the principal goals of molecular dynamics simulations. However, single long simulation frequently produces incorrectly converged quantitative results due to inadequate sampling of conformational space in a feasible wall-clock time. Multiple short (ensemble) simulations have been shown to explore conformational space more effectively than single long simulations, but the two methods have not yet been thermodynamically compared. Here we show that, for end-state binding free energy determination methods, ensemble simulations exhibit significantly enhanced thermodynamic sampling over single long simulations and result in accurate and converged relative binding free energies that are reproducible to within 0.5 kcal/mol. Completely correct ranking is obtained for six HIV-1 protease variants bound to lopinavir with a correlation coefficient of 0.89 and a mean relative deviation from experiment of 0.9 kcal/mol. Multidrug resistance to lopinavir is enthalpically driven and increases through a decrease in the protein-ligand van der Waals interaction, principally due to the V82A/I84V mutation, and an increase in net electrostatic repulsion due to water-mediated disruption of protein-ligand interactions in the catalytic region. Furthermore, we correctly rank, to within 1 kcal/mol of experiment, the substantially increased chemical potency of lopinavir binding to the wild-type protease compared to saquinavir and show that lopinavir takes advantage of a decreased net electrostatic repulsion to confer enhanced binding. Our approach is dependent on the combined use of petascale computing resources and on an automated simulation workflow to attain the required level of sampling and turn around time to obtain the results, which can be as little as three days. This level of performance promotes integration of such methodology with clinical decision support systems for the optimization of patient-specific therapy.},
  doi         = {10.1021/ci100007w},
  institution = {Centre for Computational Science, Department of Chemistry, University College London, London, WC1H 0AJ, United Kingdom.},
  language    = {eng},
  medline-pst = {ppublish},
  owner       = {dave},
  pmid        = {20384328},
  timestamp   = {2010.06.01},
  url         = {http://dx.doi.org/10.1021/ci100007w},
}

@Article{Wan2017brd4,
  author    = {S. Wan and A. P. Bhati and S. J. Zasada and I. Wall and D. Green and P. Bamborough and P. V. Coveney},
  title     = {Rapid and Reliable Binding Affinity Prediction of Bromodomain Inhibitors: a Computational Study},
  journal   = {J. Chem. Theory Comput.},
  year      = {2017},
  volume    = {13},
  number    = {2},
  pages     = {784--795},
  doi       = {10.1021/acs.jctc.6b00794},
  publisher = {ACS Publications},
}

@Article{Wan2017trk,
  author    = {S. Wan and A. P. Bhati and S. Skerratt and K. Omoto and V. Shanmugasundaram and S. K. Bagal and P. V. Coveney},
  title     = {Evaluation and Characterization of Trk Kinase Inhibitors for the Treatment of Pain: Reliable Binding Affinity Predictions from Theory and Computation},
  journal   = {J. Chem. Inf. Model},
  year      = {2017},
  volume    = {57},
  number    = {4},
  pages     = {897--909},
  doi       = {10.1021/acs.jcim.6b00780},
  publisher = {ACS Publications},
}

@Article{Karplus2005,
  author          = {Karplus, M and Kuriyan, J},
  title           = {Molecular dynamics and protein function.},
  journal         = {Proc. Natl. Acad. Sci. U.S.A.},
  year            = {2005},
  volume          = {102},
  pages           = {6679--6685},
  month           = may,
  issn            = {0027-8424},
  __markedentry   = {[dave:6]},
  abstract        = {A fundamental appreciation for how biological macromolecules work requires knowledge of structure and dynamics. Molecular dynamics simulations provide powerful tools for the exploration of the conformational energy landscape accessible to these molecules, and the rapid increase in computational power coupled with improvements in methodology makes this an exciting time for the application of simulation to structural biology. In this Perspective we survey two areas, protein folding and enzymatic catalysis, in which simulations have contributed to a general understanding of mechanism. We also describe results for the F(1) ATPase molecular motor and the Src family of signaling proteins as examples of applications of simulations to specific biological systems.},
  chemicals       = {Antineoplastic Agents, Benzamides, Enzymes, Piperazines, Proteins, Pyrimidines, Hydrogen, Imatinib Mesylate, Proto-Oncogene Proteins c-abl, src-Family Kinases, Proton-Translocating ATPases, Oxygen},
  citation-subset = {IM},
  completed       = {2005-08-01},
  country         = {United States},
  created         = {2005-05-11},
  doi             = {10.1073/pnas.0408930102},
  issn-linking    = {0027-8424},
  issue           = {19},
  keywords        = {Animals; Antineoplastic Agents, pharmacology; Benzamides; Biophysics, methods; Catalysis; Computational Biology, methods; Computer Simulation; Enzymes, chemistry; Humans; Hydrogen, chemistry; Imatinib Mesylate; Models, Molecular; Monte Carlo Method; Oxygen, chemistry; Piperazines, pharmacology; Protein Conformation; Protein Folding; Protein Structure, Tertiary; Proteins, chemistry; Proto-Oncogene Proteins c-abl, chemistry; Proton-Translocating ATPases, chemistry; Pyrimidines, pharmacology; Software; Thermodynamics; Time Factors; src-Family Kinases, chemistry},
  nlm             = {PMC1100762},
  nlm-id          = {7505876},
  owner           = {NLM},
  pii             = {0408930102},
  pmc             = {PMC1100762},
  pmid            = {15870208},
  pubmodel        = {Print-Electronic},
  pubstatus       = {ppublish},
  revised         = {2017-02-19},
}

@Article{Wan2011,
  author      = {S. Wan and P. V. Coveney},
  title       = {{Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs.}},
  journal     = {J. R. Soc. Interface},
  year        = {2011},
  volume      = {8},
  number      = {61},
  pages       = {1114--1127},
  abstract    = {The epidermal growth factor receptor (EGFR) is a major target for drugs in treating lung carcinoma. Mutations in the tyrosine kinase domain of EGFR commonly arise in human cancers, which can cause drug sensitivity or resistance by influencing the relative strengths of drug and ATP-binding. In this study, we investigate the binding affinities of two tyrosine kinase inhibitors-AEE788 and Gefitinib-to EGFR using molecular dynamics simulation. The interactions between these inhibitors and the EGFR kinase domain are analysed using multiple short (ensemble) simulations and the molecular mechanics/Poisson-Boltzmann solvent area (MM/PBSA) method. Here, we show that ensemble simulations correctly rank the binding affinities for these systems: we report the successful ranking of each drug binding to a variety of EGFR sequences and of the two drugs binding to a given sequence, using petascale computing resources, within a few days.},
  doi         = {10.1098/rsif.2010.0609},
  institution = {Centre for Computational Science, Chemistry Department, University College London, , 20 Gordon Street, London WC1H 0AJ, UK.},
  language    = {eng},
  medline-pst = {aheadofprint},
  owner       = {dave},
  pii         = {rsif.2010.0609},
  pmid        = {21227963},
  timestamp   = {2011.01.18},
  url         = {http://dx.doi.org/10.1098/rsif.2010.0609},
}

@Article{Wan2015,
  author    = {S. Wan and B. Knapp and D. W. Wright and C. M. Deane and P. V. Coveney},
  title     = {Rapid, Precise, and Reproducible Prediction of Peptide--{MHC} Binding Affinities from Molecular Dynamics That Correlate Well with Experiment},
  journal   = {J. Chem. Theory Comput.},
  year      = {2015},
  volume    = {11},
  number    = {7},
  pages     = {3346--3356},
  doi       = {10.1021/acs.jctc.5b00179},
  publisher = {ACS Publications},
}

@Article{Wright2014,
  author    = {D. W. Wright and B. A. Hall and O. A. Kenway and S. Jha and P. V. Coveney},
  title     = {Computing clinically relevant binding free energies of {HIV-}1 protease inhibitors},
  journal   = {J. Chem. Theory Comput.},
  year      = {2014},
  volume    = {10},
  number    = {3},
  pages     = {1228--1241},
  doi       = {10.1021/ct4007037},
  publisher = {ACS Publications},
}

@Article{Maier2015,
  author    = {J. A. Maier and C. Martinez and K. Kasavajhala and L. Wickstrom and K. E. Hauser and C. Simmerling},
  title     = {{ff14SB}: improving the accuracy of protein side chain and backbone parameters from {ff99SB}},
  journal   = {J. Chem. Theory Comput.},
  year      = {2015},
  volume    = {11},
  number    = {8},
  pages     = {3696--3713},
  publisher = {ACS Publications},
}

@Article{Massova1999,
  author      = {I. Massova and P.A. Kollman},
  title       = {Computational Alanine Scanning To Probe Protein-Protein Interactions: {A} Novel Approach To Evaluate Binding Free Energies},
  journal     = {J. Am. Chem. Soc.},
  year        = {1999},
  volume      = {121},
  number      = {36},
  pages       = {8133--8143},
  issn        = {0002-7863},
  affiliation = {Contribution from the Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143-0446},
  owner       = {dave},
  timestamp   = {2008.06.29},
}

@Article{MillerIII2012,
  author    = {B. R. {Miller III} and T. D. {McGee Jr} and J. M. Swails and N. Homeyer and H. Gohlke and A. E. Roitberg},
  title     = {{MMPBSA. py}: an efficient program for end-state free energy calculations},
  journal   = {J. Chem. Theory Comput.},
  year      = {2012},
  volume    = {8},
  number    = {9},
  pages     = {3314--3321},
  publisher = {ACS Publications}
}

@Misc{amber14,
  author       = {D. A. Case and V. Babin and J. T. Berryman and R. M. Betz and Q. Cai and D. S. Cerutti and T. E. Cheatham and III and T. A. Darden and R. E. Duke and H. Gohlke and A. W. Goetz and S. Gusarov and N. Homeyer and P. Janowski and J. Kaus and I. Kolossv√°ry and A. Kovalenko and T. S. Lee and S. LeGrand and T. Luchko and R. Luo and B. Madej and K. M. Merz and F. Paesani and D. R. Roe and A. Roitberg and C. Sagui and R. Salomon-Ferrer and G. Seabra and C. L. Simmerling and W. Smith and J. Swails and R. C. Walker and J. Wang and R. M. Wolf and X. Wu and P. A. Kollman},
  title        = {Amber 14},
  howpublished = {University of California, San Francisco},
  year         = {2014},
}

@Article{Bhati2017,
  author    = {A. P. Bhati and S. Wan and D. W. Wright and P. V. Coveney},
  title     = {Rapid, accurate, precise and reliable relative free energy prediction using ensemble based thermodynamic integration},
  journal   = {J. Chem. Theory Comput.},
  year      = {2017},
  volume    = {13},
  number    = {1},
  pages     = {210--222},
  doi       = {10.1021/acs.jctc.6b00979},
  publisher = {ACS Publications},
}

@Article{Bunney2015,
  author        = {T. D. Bunney and S. Wan and N. Thiyagarajan and L. Sutto and S. V. Williams and P. Ashford and H. Koss and M. A. Knowles and F. L. Gervasio and P. V. Coveney and M. Katan},
  title         = {The effect of mutations on drug sensitivity and kinase activity of fibroblast growth factor receptors: a combined experimental and theoretical study},
  journal       = {EBioMedicine},
  year          = {2015},
  volume        = {2},
  number        = {3},
  pages         = {194--204},
  __markedentry = {[dave:6]},
  doi           = {10.1016/j.ebiom.2015.02.009},
  publisher     = {Elsevier},
}

@Article{Case2005,
  author    = {D. A. Case and T. E. Cheatham and T. Darden and H. Gohlke and R. Luo and K. M. Merz and A. Onufriev and C. Simmerling and B. Wang and R. J. Woods},
  title     = {The {A}mber biomolecular simulation programs.},
  journal   = {J. Comput. Chem.},
  year      = {2005},
  volume    = {26},
  number    = {16},
  pages     = {1668--1688},
  abstract  = {We describe the development, current features, and some directions for future development of the Amber package of computer programs. This package evolved from a program that was constructed in the late 1970s to do Assisted Model Building with Energy Refinement, and now contains a group of programs embodying a number of powerful tools of modern computational chemistry, focused on molecular dynamics and free energy calculations of proteins, nucleic acids, and carbohydrates.},
  doi       = {10.1002/jcc.20290},
  keywords  = {Algorithms; Carbohydrates; Computer Simulation; Models, Biological; Models, Chemical; Models, Molecular; Nucleic Acids; Proteins; Software; Thermodynamics},
  owner     = {dave},
  pmid      = {16200636},
  timestamp = {2007.04.25},
  url       = {http://dx.doi.org/10.1002/jcc.20290},
}

@Article{Phillips2005,
  author    = {J. C. Phillips and R. Braun and W. Wang and J. Gumbart and E. Tajkhorshid and E. Villa and C. Chipot and R. D. Skeel and L. Kal\'{e} and K. Schulten},
  title     = {{S}calable molecular dynamics with {NAMD}.},
  journal   = {J. Comput. Chem.},
  year      = {2005},
  volume    = {26},
  number    = {16},
  pages     = {1781--1802},
  abstract  = {NAMD is a parallel molecular dynamics code designed for high-performance simulation of large biomolecular systems. NAMD scales to hundreds of processors on high-end parallel platforms, as well as tens of processors on low-cost commodity clusters, and also runs on individual desktop and laptop computers. NAMD works with AMBER and CHARMM potential functions, parameters, and file formats. This article, directed to novices as well as experts, first introduces concepts and methods used in the NAMD program, describing the classical molecular dynamics force field, equations of motion, and integration methods along with the efficient electrostatics evaluation algorithms employed and temperature and pressure controls used. Features for steering the simulation across barriers and for calculating both alchemical and conformational free energy differences are presented. The motivations for and a roadmap to the internal design of NAMD, implemented in C++ and based on Charm++ parallel objects, are outlined. The factors affecting the serial and parallel performance of a simulation are discussed. Finally, typical NAMD use is illustrated with representative applications to a small, a medium, and a large biomolecular system, highlighting particular features of NAMD, for example, the Tcl scripting language. The article also provides a list of the key features of NAMD and discusses the benefits of combining NAMD with the molecular graphics/sequence analysis software VMD and the grid computing/collaboratory software BioCoRE. NAMD is distributed free of charge with source code at www.ks.uiuc.edu.},
  doi       = {10.1002/jcc.20289},
  keywords  = {Algorithms, Aquaporins, Biological, Cell Membrane, Chemical, Computer Simulation, Electrostatics, Extramural, Glycophorin, Models, Molecular, N.I.H., Non-U.S. Gov't, P.H.S., Repressor Proteins, Research Support, Software, Software Design, U.S. Gov't, Ubiquitin, 16222654},
  owner     = {wright},
  pmid      = {16222654},
  timestamp = {2006.08.21},
  url       = {http://dx.doi.org/10.1002/jcc.20289},
}

@Article{Wang2004,
  author    = {J. Wang and R. M. Wolf and J. W. Caldwell and P. A. Kollman and D. A. Case},
  title     = {Development and testing of a general {A}mber force field.},
  journal   = {J. Comput. Chem.},
  year      = {2004},
  volume    = {25},
  number    = {9},
  pages     = {1157--1174},
  abstract  = {We describe here a general Amber force field (GAFF) for organic molecules. GAFF is designed to be compatible with existing Amber force fields for proteins and nucleic acids, and has parameters for most organic and pharmaceutical molecules that are composed of H, C, N, O, S, P, and halogens. It uses a simple functional form and a limited number of atom types, but incorporates both empirical and heuristic models to estimate force constants and partial atomic charges. The performance of GAFF in test cases is encouraging. In test I, 74 crystallographic structures were compared to GAFF minimized structures, with a root-mean-square displacement of 0.26 A, which is comparable to that of the Tripos 5.2 force field (0.25 A) and better than those of MMFF 94 and CHARMm (0.47 and 0.44 A, respectively). In test II, gas phase minimizations were performed on 22 nucleic acid base pairs, and the minimized structures and intermolecular energies were compared to MP2/6-31G* results. The RMS of displacements and relative energies were 0.25 A and 1.2 kcal/mol, respectively. These data are comparable to results from Parm99/RESP (0.16 A and 1.18 kcal/mol, respectively), which were parameterized to these base pairs. Test III looked at the relative energies of 71 conformational pairs that were used in development of the Parm99 force field. The RMS error in relative energies (compared to experiment) is about 0.5 kcal/mol. GAFF can be applied to wide range of molecules in an automatic fashion, making it suitable for rational drug design and database searching.},
  doi       = {10.1002/jcc.20035},
  keywords  = {Nucleic Acids; Proteins; Thermodynamics},
  owner     = {dave},
  pmid      = {15116359},
  timestamp = {2007.04.25},
  url       = {http://dx.doi.org/10.1002/jcc.20035},
}

@Article{Karplus2002,
  author  = {M. Karplus and J. A. McCammon},
  title   = {Molecular dynamics simulations of biomolecules},
  journal = {Nat. Struct. Mol. Biol.},
  year    = {2002},
  volume  = {9},
  pages   = {646--652},
}

@Article{Siegel2016,
  author   = {Siegel, R. L. and Miller, K. D. and Jemal, A.},
  title    = {Cancer statistics, 2016},
  journal  = {{CA}: A Cancer Journal for Clinicians},
  year     = {2016},
  volume   = {66},
  number   = {1},
  pages    = {7--30},
  issn     = {1542-4863},
  doi      = {10.3322/caac.21332},
  keywords = {cancer cases, cancer statistics, death rates, incidence, mortality, survival, trends},
  url      = {http://dx.doi.org/10.3322/caac.21332},
}

@Article{Li2016,
  author    = {Li, Ying Hong AND Wang, Pan Pan AND Li, Xiao Xu AND Yu, Chun Yan AND Yang, Hong AND Zhou, Jin AND Xue, Wei Wei AND Tan, Jun AND Zhu, Feng},
  title     = {The Human Kinome Targeted by {FDA} Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective},
  journal   = {{PLOS ONE}},
  year      = {2016},
  volume    = {11},
  number    = {11},
  pages     = {1-15},
  month     = {11},
  abstract  = {The human kinome is one of the most productive classes of drug target, and there is emerging necessity for treating complex diseases by means of polypharmacology (multi-target drugs and combination products). However, the advantages of the multi-target drugs and the combination products are still under debate. A comparative analysis between FDA approved multi-target drugs and combination products, targeting the human kinome, was conducted by mapping targets onto the phylogenetic tree of the human kinome. The approach of network medicine illustrating the drug-target interactions was applied to identify popular targets of multi-target drugs and combination products. As identified, the multi-target drugs tended to inhibit target pairs in the human kinome, especially the receptor tyrosine kinase family, while the combination products were able to against targets of distant homology relationship. This finding asked for choosing the combination products as a better solution for designing drugs aiming at targets of distant homology relationship. Moreover, sub-networks of drug-target interactions in specific disease were generated, and mechanisms shared by multi-target drugs and combination products were identified. In conclusion, this study performed an analysis between approved multi-target drugs and combination products against the human kinome, which could assist the discovery of next generation polypharmacology.},
  doi       = {10.1371/journal.pone.0165737},
  publisher = {Public Library of Science},
  url       = {https://doi.org/10.1371/journal.pone.0165737},
}

@Article{Ash2017,
  author  = {Ash, Jeremy and Fourches, Denis},
  title   = {Characterizing the Chemical Space of {ERK2} Kinase Inhibitors Using Descriptors Computed from Molecular Dynamics Trajectories},
  journal = {J. Chem. Inf. Model.},
  year    = {2017},
  volume  = {57},
  number  = {6},
  pages   = {1286-1299},
  note    = {PMID: 28471171},
  doi     = {10.1021/acs.jcim.7b00048},
  eprint  = {http://dx.doi.org/10.1021/acs.jcim.7b00048},
  url     = { 
        http://dx.doi.org/10.1021/acs.jcim.7b00048
    
},
}

@Article{DeVivo2016,
  author  = {De Vivo, Marco and Masetti, Matteo and Bottegoni, Giovanni and Cavalli, Andrea},
  title   = {Role of Molecular Dynamics and Related Methods in Drug Discovery},
  journal = {Journal of Medicinal Chemistry},
  year    = {2016},
  volume  = {59},
  number  = {9},
  pages   = {4035-4061},
  note    = {PMID: 26807648},
  doi     = {10.1021/acs.jmedchem.5b01684},
  eprint  = {http://dx.doi.org/10.1021/acs.jmedchem.5b01684},
  url     = { 
        http://dx.doi.org/10.1021/acs.jmedchem.5b01684
    
},
}

@Comment{jabref-meta: databaseType:bibtex;}
